Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002)
Alessandro D. Santin(Yale University), Michael J. Birrer(University of Arkansas Medical Center), Samir N. Khleif(Georgetown University), Wei Deng(Wuhan University), Heather A. Lankes(Nationwide Children's Hospital), Amir A. Jazaeri(The University of Texas MD Anderson Cancer Center), Roisin E. O’Cearbhaill(Memorial Sloan Kettering Cancer Center), Natália Buza(Yale University), Warner K. Huh(University of Alabama at Birmingham), Michael Frumovitz(The University of Texas MD Anderson Cancer Center), Stefania Bellone(Yale University), Elena Ratner(Yale University)
Cited by 155
Related Papers
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
Breast cancer classification and prognosis based on gene expression profiles from a population-based study
|Proceedings of the National Academy of Sciences|2003|2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
|Journal of Clinical Oncology|2012|1.2k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846